Cytek Biosciences stock
CTKBNASDAQCytek Biosciences, Inc., HealthcareISIN US23285D1090
47Score 47 out of 100, Weak
Price and trend
83 / 100
Price history
+15% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 18% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 12% below its 52-week high. Largest decline in 5 years: 91% (September 2021 to May 2025).
Chart figures for advanced users
- SMA 50$5.48
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.67
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.36
- The lowest closing price of the last twelve months.
- Resistance$6.30
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Cytek Biosciences, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $721.93M, is number 68 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $201.49M (up 0.5% year on year) and a loss of $66.54M.
- MEQIRI Score 47 out of 100 (Weak): rank 423 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $255.9M, financial debt $24.69M.Stability 56
Weaknesses
- Loss-makingLoss of $81.2M over the last 12 months.Fundamentals 23
- Turned to a lossEarnings per share from $0.02 in 2020 to −$0.52.Growth 38
- Negative free cash flowFree cash flow −$13.48M over the last 12 months.Fundamentals 23
Its standout strengths are momentum and technical analysis, while profitability and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.5% on the twelve months before. Revenue has grown strongly since 2019, at around 23% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 52%, operating −20%, net −33%. Last 12 months: net −39%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 4 Nov 2026EPS reported −$0.05 (expected −$0.07)above expectations
Analyst estimates
- Earnings per share
- −$0.30+13.6%
- Revenue
- $209.19M−0.1%
- Earnings per share
- −$0.18+28.6%
- Revenue
- $222.74M−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −2.8%Low end of the 2026 revenue guidance raised, new range $207 million to $212 million (midpoint up $1 million); adjusted EBITDA around break-even.
“Turning to slide 10, today we are raising the low end of our full year 2026 revenue guidance range so that the revised range is $207 million to $212 million, increasing the midpoint by $1 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Cytek Biosciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Beta BionicsBBNX $801.27M47
- InModeINMD $790.08M72
- Varex ImagingVREX $780.9M53
- Delcath SystemsDCTH $757.34M64
- BioventusBVS $752.53M61
- Synektik Spólka AkcyjnaSNT.WA $709.44M77
- Senseonics HoldingsSENS $684.97M44
- Xvivo PerfusionXVIVO.ST $653.35M50
ETFs that hold Cytek Biosciences
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.07% | 0.40% | €1.49B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jan 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.